This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBIO Catalyst Biosciences (CBIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Catalyst Biosciences Stock (NASDAQ:CBIO) 30 days 90 days 365 days Advanced Chart Get Catalyst Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.34▼$7.6752-Week Range N/AVolume32,246 shsAverage Volume763,526 shsMarket Capitalization$291.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Read More… Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CBIO Stock News HeadlinesCatalyst Biosciences Inc trading halted, volatility trading pauseMarch 19, 2025 | markets.businessinsider.comBiocom California Names the Ninth Annual Life Science Catalyst Award WinnersOctober 29, 2024 | businesswire.comElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Trump himself said Musk was a "once-in-a-generation industry leader." The president has put him to work as an efficiency czar through the newly created DOGE.May 1, 2025 | Weiss Ratings (Ad)Catalyst Mutual FundsOctober 4, 2024 | morningstar.comCaribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene EditingSeptember 30, 2024 | seekingalpha.comStrong Buy Recommendation for Cellectar Biosciences on Positive Phase 2b Results and Solid FinancialsAugust 17, 2024 | markets.businessinsider.comCastle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comNeurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional UpsideFebruary 10, 2024 | seekingalpha.comSee More Headlines CBIO Stock Analysis - Frequently Asked Questions How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences, Inc. (NASDAQ:CBIO) released its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). When did Catalyst Biosciences' stock split? Catalyst Biosciences's stock reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Catalyst Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/17/2023Today5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:CBIO CIK1124105 Webwww.catalystbiosciences.com Phone(650) 871-0761Fax336-480-2107Employees7Year Founded2003Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-364.68% Return on Assets-281.68% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual Sales$790,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.78) per share Price / BookN/AMiscellaneous Outstanding Shares37,980,000Free Float36,869,000Market Cap$291.29 million OptionableOptionable Beta1.05 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:CBIO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.